DB15805InvestigationalVaccines
SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture. The... The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd..
- Code names
- SCB-2019
What you can answer from here — as of October 29, 2025
Which companies are running trials of SCB-2019, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account